H.R.5101 - Affordable HIV/AIDS Medicines for Poor Countries Act106th Congress (1999-2000)
|Sponsor:||Rep. Waters, Maxine [D-CA-35] (Introduced 07/27/2000)|
|Committees:||House - Ways and Means; International Relations|
|Latest Action:||House - 07/27/2000 Referred to the Committee on Ways and Means, and in addition to the Committee on International Relations, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.5101 — 106th Congress (1999-2000)All Information (Except Text)
Affordable HIV-AIDS Medicines for Poor Countries Act - Directs the Secretary of the Treasury, the Administrator of the U.S. Agency for International Development, and the U.S. Trade Representative (USTR) to encourage developing countries (including sub-Saharan African countries) and pharmaceutical companies to make HIV-AIDS pharmaceuticals and medical technologies available to people who live in such countries without charge or at affordable prices.
Introduced in House (07/27/2000)
Sets forth certain restrictions and limitations, including that: (1) appropriated funds made available to U.S. agencies may not be obligated to seek the revocation or revision of any intellectual property or competition law or policy of a developing country (including any sub- Saharan African country) that regulates HIV-AIDS pharmaceuticals or medical technologies if such law or policy promotes access to such drugs and technologies to the country's population; and (2) the USTR may not initiate a proceeding in the World Trade Organization (WTO) challenging and law or policy of a developing country (including a sub-Saharan African country) that promotes access to HIV-AIDS pharmaceuticals or medical technologies to the population of the country.
Requires the President to direct the U.S. representative to the WTO to urge the WTO and member countries to exempt developing countries (including sub-Saharan African countries) from the application of any provision of the Agreement on Trade-Related Aspects of Intellectual Property Rights or any other international agreement relating to intellectual property rights that would prohibit or restrict such countries from establishing or implementing any law or policy that promotes access to HIV-AIDS pharmaceuticals or medical technologies to their population.